<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756209</url>
  </required_header>
  <id_info>
    <org_study_id>Migraine2010</org_study_id>
    <nct_id>NCT01756209</nct_id>
  </id_info>
  <brief_title>Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood</brief_title>
  <official_title>The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catanzaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: The purpose of this study was to evaluate both the effects of ibuprofen and/or
      acetaminophen for the acute treatment of primary migraine in children in or out prophylactic
      treatment with magnesium.

      Methods: The study had been approved by the Researchers Ethics Committee of the
      &quot;Pugliese-Ciaccio&quot; Hospital (protocol number 720/2010; EUDRACT NUMBER 2012-005737-36) and the
      children ranging from the ages of 5 to 18 years with at least four attack/month of primary
      migraine were enrolled. A Visual Analogical Scale was used to evaluate pain intensity at the
      moment of admission to the study (start of the study) and every month up to 18 months later
      (end of the study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design The present work is a single-blind, balanced recruitment, parallel-group, single
      center study in outpatient children enrolled at the Pediatric Unit-Pugliese Ciaccio Hospital
      in Catanzaro, Italy, between January 2010 and June 2010.

      This study had been approved by the Researchers Ethics Committee of the &quot;Pugliese-Ciaccio&quot;
      Hospital (protocol number 720/2010; EUDRACT NUMBER 2012-005737-36), and was conducted
      following the Declaration of Helsinki and the Guidelines for Good Clinical Practice criteria.

      Population Children with migraine without aura (MoA) of both sexes aged from 5 to 16 years,
      with at least four attacks /month, were eligible for the study. MoA was diagnosed according
      to the criteria for pediatric age of the International Classification of Headache Disorders
      (IHS-2) [22].

      Exclusion criteria were the following: mental retardation (IQ &lt;70), genetic syndromes (e.g.,
      Down syndrome, Prader-Willi syndrome, fragile X syndrome), hypothyroidism, psychiatric
      disorders (i.e.: schizophrenia, mood disorders, ADHD), neuromuscular disorders, epilepsy,
      obesity (BMI&gt;95 percentiles), liver or renal diseases, gastrointestinal disorders such as
      peptic or duodenal ulcer, dyspepsia, or heartburn; hypersensitivity to medication studies.

      Informed written consent was obtained by parents.

      Experimental protocol In a balanced recruitment study eligible outpatients with primary acute
      migraine were assigned to receive at pain onset: acetaminophen (15mg/kg) or ibuprofen
      (10mg/kg). Moreover, in order to evaluate the prophylaxis effect of magnesium in another set
      of experiments eligible children were assigned to receive a daily magnesium supplement (400
      mg/daily) and then one single dose of acetaminophen (15mg/kg) or ibuprofen (10 mg/kg) at the
      time of pain (Figure 1). In this study, in agreement with the Declaration of Helsinki (1991),
      we did not use a placebo group.

      In each group, children were assigned in accordance to age, gender in order to obtain similar
      groups of treatment.

      In order to assess the intensity of pain, before and up to 3 hours after the administration
      of both drugs used in the present protocol, a non standardized ad hoc scale and a visual
      analogical scale (VAS) were used.

      Specifically, for the pre-dose assessments, the pain intensity was measured on an arbitrarily
      established categoric scales in response to the question, &quot;What is your pain level at this
      time?&quot; with response choices from 0 to 3, where 0 = none; 1 = mild; 2 = moderate; and 3 =
      severe. In addition, a visual analogical scale (VAS) was used to assess pain severity before,
      during and after the treatment. Patients were asked to draw a single vertical line on the
      100-mm VAS, where 0 = no pain (score 0) and 100 mm = worst pain (score 10). This scale had
      been previously used to measure pain in pediatric populations .

      The safety on medication studies was assessed in terms of frequency and nature of adverse
      drug reactions (ADRs). In order to evaluate the association between ADRs and drug treatment,
      the Naranjo Adverse Probability Scale was applied .

      Number, duration, severity of pain attacks, analgesic intake and the occurrence of ADRs were
      recorded in a daily diary card 1 month prior to the trial and subsequently during the entire
      period of the study. For each patient, follow-up sessions were planned every month after
      enrollment and continued for 18 months (end of the study).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-relief</measure>
    <time_frame>3 and 18 months</time_frame>
    <description>The primary endpoint was when pain-relief took place and pain intensity differences from baseline (0 hour) to 3 hours after drug treatment. This measurement was defined as the AUC for the sum of the 2 measurements (pain relief and pain intensity difference) at each time point from 0 to 3 hours.
Pain was measured using the vas analogue scale (range 0-10, where 0 = no pain (score 0) and 100 mm = worst pain (score 10)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 15 mg/kg oral single dose (n=40)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 10 mg/kg oral single dose (n=40)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen + magnesium 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen 15 mg/kg oral single dose (n=40) + magnesium 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen + magnesium 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibuprofen 10 mg/kg oral single dose (n=40) + magnesium 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium 400Mg</intervention_name>
    <description>magnesium 400 mg + conventional treatment</description>
    <arm_group_label>Acetaminophen + magnesium 400 mg</arm_group_label>
    <arm_group_label>ibuprofen + magnesium 400 mg</arm_group_label>
    <other_name>magnesium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 10 mg/kg</intervention_name>
    <description>ibuprofen 10 mg/kg oral single dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_label>ibuprofen + magnesium 400 mg</arm_group_label>
    <other_name>ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen 15 mg/kg</intervention_name>
    <description>Acetaminophen 15 mg/kg oral single dose</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_label>Acetaminophen + magnesium 400 mg</arm_group_label>
    <other_name>acetaminophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with migraine without aura (MoA) diagnosed according to the criteria for
             pediatric age of the International Classification of Headache Disorders (IHS-2)

          -  aged from 5 to 18 years

          -  at least four attacks /month

        Exclusion Criteria:

          -  mental retardation (IQ &lt;70)

          -  genetic syndromes (e.g., Down syndrome, Prader-Willi syndrome, fragile X syndrome)

          -  hypothyroidism

          -  psychiatric disorders (i.e.: schizophrenia, mood disorders, ADHD),

          -  neuromuscular disorders,

          -  epilepsy,

          -  obesity (BMI&gt;95 percentiles),

          -  liver or renal diseases,

          -  gastrointestinal disorders such as peptic or duodenal ulcer, dyspepsia, or heartburn;

          -  hypersensitivity to medication studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>In each group, children were assigned in accordance to age and gender in order to obtain similar groups of treatment.</gender_description>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Peltrone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pugliese Ciaccio Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pugliese Ciaccio Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2012</study_first_posted>
  <results_first_submitted>May 11, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2020</results_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen</title>
          <description>Acetaminophen 15 mg/kg oral single dose</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 10 mg/kg oral single dose</description>
        </group>
        <group group_id="P3">
          <title>Mg + Acetaminophen</title>
          <description>Magnesium 400 mg/daily + Acetaminophen 15 mg/kg oral single dose</description>
        </group>
        <group group_id="P4">
          <title>Mg + Ibuprofen</title>
          <description>Magnesium 400 mg/daily + Ibuprofen 10 mg/kg oral single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen</title>
          <description>Acetaminophen 15 mg/kg oral single dose</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 10 mg/kg oral single dose</description>
        </group>
        <group group_id="B3">
          <title>Mg + Acetaminophen</title>
          <description>Magnesium 400 mg/daily + Acetaminophen 15 mg/kg oral single dose</description>
        </group>
        <group group_id="B4">
          <title>Mg + Ibuprofen</title>
          <description>Magnesium 400 mg/daily + Ibuprofen 10 mg/kg oral single dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pain visual analog scale (range 0 (better) -100 (worse) mm)</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.95" spread="2.9"/>
                    <measurement group_id="B2" value="6.55" spread="2.85"/>
                    <measurement group_id="B3" value="7.57" spread="2.55"/>
                    <measurement group_id="B4" value="7.35" spread="2.93"/>
                    <measurement group_id="B5" value="7.11" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain-relief</title>
        <description>The primary endpoint was when pain-relief took place and pain intensity differences from baseline (0 hour) to 3 hours after drug treatment. This measurement was defined as the AUC for the sum of the 2 measurements (pain relief and pain intensity difference) at each time point from 0 to 3 hours.
Pain was measured using the vas analogue scale (range 0-10, where 0 = no pain (score 0) and 100 mm = worst pain (score 10)</description>
        <time_frame>3 and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen</title>
            <description>Acetaminophen 15 mg/kg oral single dose</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 10 mg/kg oral single dose</description>
          </group>
          <group group_id="O3">
            <title>Mg + Acetaminophen</title>
            <description>Magnesium 400 mg/daily + Acetaminophen 15 mg/kg oral single dose</description>
          </group>
          <group group_id="O4">
            <title>Mg + Ibuprofen</title>
            <description>Magnesium 400 mg/daily + Ibuprofen 10 mg/kg oral single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Pain-relief</title>
          <description>The primary endpoint was when pain-relief took place and pain intensity differences from baseline (0 hour) to 3 hours after drug treatment. This measurement was defined as the AUC for the sum of the 2 measurements (pain relief and pain intensity difference) at each time point from 0 to 3 hours.
Pain was measured using the vas analogue scale (range 0-10, where 0 = no pain (score 0) and 100 mm = worst pain (score 10)</description>
          <units>units on a scale*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.5"/>
                    <measurement group_id="O2" value="5.1" spread="0.6"/>
                    <measurement group_id="O3" value="2.25" spread="0.3"/>
                    <measurement group_id="O4" value="2.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>adverse events were collected in the clinical diary of each patient</desc>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen</title>
          <description>Acetaminophen 15 mg/kg oral single dose</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 10 mg/kg oral single dose</description>
        </group>
        <group group_id="E3">
          <title>Mg + Acetaminophen</title>
          <description>Magnesium 400 mg/daily + Acetaminophen 15 mg/kg oral single dose</description>
        </group>
        <group group_id="E4">
          <title>Mg + Ibuprofen</title>
          <description>Magnesium 400 mg/daily + Ibuprofen 10 mg/kg oral single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Francesco Peltrone, Responsible of clinical trial</name_or_title>
      <organization>Pugliese Hospital of Catanzaro</organization>
      <phone>+.39 0961 7123222</phone>
      <email>gallelli@unicz.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

